Diagnostics News and Research RSS Feed - Diagnostics News and Research

SCRA Technology Ventures announces sale of Selah Genomics to EKF Diagnostics

SCRA Technology Ventures announces sale of Selah Genomics to EKF Diagnostics

SCRA Technology Ventures today announced that portfolio company Selah Genomics was sold to EKF Diagnostics, a publically-traded UK-based diagnostics firm. Selah, a provider of advanced molecular and genomic diagnostic services, completed the deal today, making it the largest of nine exits out of the SC Launch program since 2006. [More]

OPKO Health enters into definitive agreement to acquire Inspiro Medical

OPKO Health, Inc. has entered into a definitive agreement to acquire Inspiro Medical Ltd., an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. Inspiro's Inspiromatic is a "smart" easy-to-use dry powder inhaler with several advantages over existing devices. [More]
Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma, today announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism, for the exclusive distribution of the company's amino acid based products to physicians and pharmacies throughout the Middle East. [More]

Findings offer new paths towards improved fertility treatments and development of new contraceptives

​Researchers at the Wellcome Trust Sanger Institute have discovered interacting proteins on the surface of the sperm and the egg essential to begin mammalian life. These proteins, which allow the sperm and egg to recognize one another, offer new paths towards improved fertility treatments and the development of new contraceptives. [More]
Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. [More]
Parabon launches Compute Against Alzheimer's Disease research initiative

Parabon launches Compute Against Alzheimer's Disease research initiative

Parabon Computation announced today the launch of the Compute Against Alzheimer's Disease (CAAD) research initiative, which will accelerate investigations into the causes and risks of Alzheimer's Disease (AD) through the application of large-scale computational capacity donated by concerned citizens and organizations. [More]

Hooper Holmes enters into Strategic Alliance Agreement with Clinical Reference Laboratory

Hooper Holmes and Clinical Reference Laboratory, Inc. today announced that they have entered into a Strategic Alliance Agreement under which CRL will become Hooper Holmes' exclusive provider of laboratory testing services and Hooper Holmes will become a member of CRL's preferred provider network for wellness programs. [More]
Researchers develop more accurate tool for diagnosing even mild cases of asthma

Researchers develop more accurate tool for diagnosing even mild cases of asthma

Using just a single drop of blood, a team of University of Wisconsin-Madison researchers has developed a faster, cheaper and more accurate tool for diagnosing even mild cases of asthma. [More]
Measurement of calcium in coronary arteries can predict heart disease risk

Measurement of calcium in coronary arteries can predict heart disease risk

With growing evidence that a measurement of the buildup of calcium in coronary arteries can predict heart disease risk, Los Angeles Biomedical Research Institute (LA BioMed) researchers found that the process of "calcium scoring" was also accurate in predicting the chances of dying of heart disease among adults with little or no known risk of heart disease. [More]
EventusDx completes $2.72M financing to support development, commercialization of Octava breast cancer tests

EventusDx completes $2.72M financing to support development, commercialization of Octava breast cancer tests

Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests. [More]

Henry Schein launches new iPad online ordering application to help veterinary practitioners

Henry Schein Animal Health, the leading companion animal health distributor in the United States, and the U.S. animal health business of Henry Schein, Inc., announced today that it has launched a new iPad® online ordering application to help veterinary practitioners manage their product purchases. [More]
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]
Genetic evidence confirms role of group of virus-fighting genes in cancer development

Genetic evidence confirms role of group of virus-fighting genes in cancer development

Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development. [More]
ICB International develops tracer for imaging alpha-synuclein in Parkinson's disease

ICB International develops tracer for imaging alpha-synuclein in Parkinson's disease

On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado. [More]

Nexstim joins 2014 Red Herring mark of distinction

Red Herring's Top 100 Europe celebrates the exceptional accomplishments of technology companies and their position to grow at an explosive rate. The awards winners were announced today, and Nexstim has proudly been selected in this prestigious group as a Top 100 Europe. [More]
EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

New ways to differentiate between chronic and self-clearing infections may help towards effective patient management and reduce drug costs. But there are major challenges in implementation. [More]
Abbott completes enrollment of 3 clinical trials to support approval of Absorb Bioresorbable Vascular Scaffold

Abbott completes enrollment of 3 clinical trials to support approval of Absorb Bioresorbable Vascular Scaffold

Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. [More]
Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept™ platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS). [More]
AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. [More]
Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China. [More]